open access

Vol 9, No 5 (2008): Practical Diabetology
Original articles (submitted)
Published online: 2008-10-23
Get Citation

Treatment intensification with insulin analogs in type 2 diabetics

Bogumił Wolnik, Monika Łukaszewicz
Diabetologia Praktyczna 2008;9(5):209-219.

open access

Vol 9, No 5 (2008): Practical Diabetology
Original articles (submitted)
Published online: 2008-10-23

Abstract

Nowadays we can observe the increasing prevalence of diabetes all over the world. Despite new hipoglycaemic drugs implementation, including modern insulin products the metabolic control of diabetes does not improve. Generally it results from too late introducing insulinotherapy or noneffective treatment intensification. In this paper we present insulin analogues efficiacy and safety profile in beginning or advancement in 1492 patients with diabetes type 2. Data were collected from observative questionnaire research of two visits with 3 months interval. The mean time of diabetes duration was 9.77 years. Mean HbA1c level - 8.86%, fasting blood glucose 160 mg/dl, postprandial glucose 216 mg/dl. The commonest cause of treatment intensification was abnormal postprandial glucose (88.5%), fasting glucose (73.8%) and HbA1c (38.6%). Modification of insulinotherapy was personalized. NovoRapid and Insulatard or NovoMix30 in monotherapy or together with NovoRapid were used. Treatment change caused decrease of HbA1c level to 7.7%, fasting glycaemia to 123.46 mg/dl and post prandial glucose to 155.32 mg/dl. Differences were statistically significant. 76.9% of patients considered the treatmnet more comfortable. Number of hypoglycaemia was lower. One of the most important factors influencing the new treatment efficiacy is better patient compliance depending on time of insulin injection - immediately before a meal.

Abstract

Nowadays we can observe the increasing prevalence of diabetes all over the world. Despite new hipoglycaemic drugs implementation, including modern insulin products the metabolic control of diabetes does not improve. Generally it results from too late introducing insulinotherapy or noneffective treatment intensification. In this paper we present insulin analogues efficiacy and safety profile in beginning or advancement in 1492 patients with diabetes type 2. Data were collected from observative questionnaire research of two visits with 3 months interval. The mean time of diabetes duration was 9.77 years. Mean HbA1c level - 8.86%, fasting blood glucose 160 mg/dl, postprandial glucose 216 mg/dl. The commonest cause of treatment intensification was abnormal postprandial glucose (88.5%), fasting glucose (73.8%) and HbA1c (38.6%). Modification of insulinotherapy was personalized. NovoRapid and Insulatard or NovoMix30 in monotherapy or together with NovoRapid were used. Treatment change caused decrease of HbA1c level to 7.7%, fasting glycaemia to 123.46 mg/dl and post prandial glucose to 155.32 mg/dl. Differences were statistically significant. 76.9% of patients considered the treatmnet more comfortable. Number of hypoglycaemia was lower. One of the most important factors influencing the new treatment efficiacy is better patient compliance depending on time of insulin injection - immediately before a meal.
Get Citation

Keywords

type 2 diabetes; aspart insulin; insulin analogues

About this article
Title

Treatment intensification with insulin analogs in type 2 diabetics

Journal

Clinical Diabetology

Issue

Vol 9, No 5 (2008): Practical Diabetology

Pages

209-219

Published online

2008-10-23

Bibliographic record

Diabetologia Praktyczna 2008;9(5):209-219.

Keywords

type 2 diabetes
aspart insulin
insulin analogues

Authors

Bogumił Wolnik
Monika Łukaszewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl